Navigation Links
Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
Date:9/17/2007

tt's Forward Looking Statements:

This press release contains forward-looking statements, including statements concerning our product development efforts. These statements constitute forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate; our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; an increase in litigation, including product liability claims and patent litigation; government regulation affecting the development, manufacture, marketin
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Charter and Time Warner to partner on fiber optics
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering and developing innovative therapies primarily ... today announced that Dr. Pamela Pavco , ... the 23 rd World Congress of ... include in-depth presentations by world-class clinicians and/or ...
(Date:6/2/2015)... 02, 2015 Through rare discovery of ... Yancy Corporation is enabling World Scientists to actually ... biological sample, displaying the full nature (position, shape, size, ... , Jeff Porter, Co-Founder of the Yancy Corporation, says, ... – rare. They come once in a lifetime, if ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 Chosen ... health care, Jack Uldrich has been selected as ... New York today. He will deliver his keynote: ... Uldrich has delivered presentations to the American Medical ... Audiology and Neurology, Alcetel-Lucent/Verizon Forum on Wireless Healthcare, ...
(Date:6/1/2015)... and RARITAN, N.J. ... Development, LLC (Janssen) announced data from the Phase ... improvement in progression-free survival (PFS) with trabectedin (YONDELIS ... advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated ... chemotherapy regimen. SAR3007 is the largest randomized Phase ...
Breaking Biology Technology:RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 2RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 3RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 4Scientists Eying Rare Discovery Of New Physics & Light Microscope Technology 2Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... , CINCINNATI , June 3 Kendle ... organization (CRO), today announced it is ranked a top CRO ... Survey. Kendle is the only CRO to be ranked consistently ... four years in the annual U.S. and European site surveys ...
... June 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... Wolff , executive vice president and CFO, will provide an update on the ... business strategy at two investor conferences during the month of June: , ... The Jefferies 2010 ...
... June 3 The John Theurer Cancer Center ... that will be presented at the American Society of Clinical ... – 8, 2010 in Chicago . Research highlights include ... lymphoma, the efficacy and safety of a new genetically engineered ...
Cached Biology Technology:Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 2Kendle Rated a Top CRO to Work with for Fourth Consecutive Year 3Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 2New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 3New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 4New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 5New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting 6
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)...  For more than four decades, AUVSI,s Unmanned ... premier worldwide event for the unmanned land, sea, and ... for any local, national, or trade news organization interested ... and current applications of unmanned technologies. The conference will ... billion industry, and how it will soon impact the ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... reverse, reveals a new study published online on November 29th ... topi antelopes, females are the ones who aggressively pursue their ... view of sexual conflict holds that males, for whom reproducing ... other hand, females, who must pay a heftier price, are ...
... . How did the rodents which inhabited the ... The researcher of the UGR Raef Minwer-Barakat ... thesis "Rodents and insectivorous of Upper Turoliense and the Pliocene ... doctors Elvira Martn and Csar Viseras, of the Dept. ...
... in EMEA spurs IdentiPHI,s company ... expansion, ... security solutions and services, announces its,expansion with the opening of an office ... and authentication (access,management) products and solutions., "Opening the office in Europe ...
Cached Biology News:In promiscuous antelopes, the 'battle of the sexes' gets flipped 2Rodent fossils allows to determine climate of the Iberian Peninsula 6 million years ago 2IdentiPHI Opens Paris Office to Boost European Sales and Support 2
... CELlulose) was developed in the late 1960s ... of the earliest commercial pioneers of immunoassay ... range in 1987. Sac-Cel rapidly found favour ... own "in house" radioimmunoassays, and became a ...
Determin interaction of your protein with Echelons lipids...
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Biology Products: